Lacidofil® Curbs IBS Symptoms

TOULOUSE, France—

Lacidofil®, a proprietary probiotic formulation from Institut Rosell, effectively reduced symptoms associated with chronic Irritable Bowel Syndrome (IBS) in patients according to a study conducted at the Thomayer’s Teaching Hospital, in Prague (Nutrafoods, 4,1:64, 2005).

In the study, 88 percent of 50 patients with a 10-year or greater history of chronic IBS experienced a reduction in IBS-related complaints after taking Lacidofil for 16 weeks. No side effects were reported and the researchers concluded that Lacidofil may be a safe and effective therapy to reduce symptoms associated with IBS.

Henri Durand, scientific director with Institut Rosell (www.institut-rosell.com), said: “Lacidofil was tested in association with conventional treatment over a four-month period, representing a relatively long lasting trial with a probiotic supplementation in IBS. The results were very encouraging as most of the patients reported improvement of their condition.”